Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

0.3850 -0.0250 (-6.10%)

Streaming Delayed Price Updated: 10:14 AM EDT, Aug 7, 2026 Add to My Watchlist

Price and Volume

Volume	112,474
Open	0.4015
Bid (Size)	0.3850 (100)
Ask (Size)	0.4000 (100)
Prev. Close	0.4100
Today's Range	0.3826 - 0.4095
52wk Range	0.3820 - 50.00
Shares Outstanding	8,024,092
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Instinct Bio Announces Strategic Collaboration With INVITRX to Expand GENREVER Into U.S. and Advance Indonesia Regenerative Medicine Initiatives

July 30, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Blade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology Conference

August 01, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Performance

YTD	-97.5%	-97.5%
1 Month	-97.5%	-97.5%
3 Month	-97.5%	-97.5%
6 Month	-97.5%	-97.5%
1 Year	-97.5%	-97.5%

More News

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

June 03, 2022

Via InvestorPlace

Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference

May 18, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

May 16, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package

April 04, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference

March 24, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

January 12, 2022

From Blade Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Instinct Bio Technical Company Holdings Inc. - Common stock publicly traded?

Yes, Instinct Bio Technical Company Holdings Inc. - Common stock is publicly traded.

What exchange does Instinct Bio Technical Company Holdings Inc. - Common stock trade on?

Instinct Bio Technical Company Holdings Inc. - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock?

The ticker symbol for Instinct Bio Technical Company Holdings Inc. - Common stock is BIOT on the Nasdaq Stock Market

What is the current price of Instinct Bio Technical Company Holdings Inc. - Common stock?

The current price of Instinct Bio Technical Company Holdings Inc. - Common stock is 0.3850

When was Instinct Bio Technical Company Holdings Inc. - Common stock last traded?

The last trade of Instinct Bio Technical Company Holdings Inc. - Common stock was at 08/07/26 10:14 AM ET

What is the market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock?

The market capitalization of Instinct Bio Technical Company Holdings Inc. - Common stock is 3.09M

How many shares of Instinct Bio Technical Company Holdings Inc. - Common stock are outstanding?

Instinct Bio Technical Company Holdings Inc. - Common stock has 3M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Instinct Bio Technical Company Holdings Inc. - Common stock (NQ:BIOT)

Price and Volume

Top News

Performance

More News

Frequently Asked Questions